Literature DB >> 28665705

Summary for Clinicians: Lymphangioleiomyomatosis Diagnosis and Management Clinical Practice Guideline.

Laura C Feemster1,2, Patrick G Lyons3, Rohini S Chatterjee4, Pranav Kidambi4, Francis X McCormack5, Joel Moss6, Kevin C Wilson7, Carey C Thomson8.   

Abstract

Entities:  

Mesh:

Year:  2017        PMID: 28665705      PMCID: PMC5566288          DOI: 10.1513/AnnalsATS.201609-685CME

Source DB:  PubMed          Journal:  Ann Am Thorac Soc        ISSN: 2325-6621


× No keyword cloud information.
  7 in total

1.  GRADE guidelines: 3. Rating the quality of evidence.

Authors:  Howard Balshem; Mark Helfand; Holger J Schünemann; Andrew D Oxman; Regina Kunz; Jan Brozek; Gunn E Vist; Yngve Falck-Ytter; Joerg Meerpohl; Susan Norris; Gordon H Guyatt
Journal:  J Clin Epidemiol       Date:  2011-01-05       Impact factor: 6.437

2.  European Respiratory Society guidelines for the diagnosis and management of lymphangioleiomyomatosis.

Authors:  S R Johnson; J F Cordier; R Lazor; V Cottin; U Costabel; S Harari; M Reynaud-Gaubert; A Boehler; M Brauner; H Popper; F Bonetti; C Kingswood
Journal:  Eur Respir J       Date:  2010-01       Impact factor: 16.671

3.  Decline in lung function in patients with lymphangioleiomyomatosis treated with or without progesterone.

Authors:  Angelo M Taveira-DaSilva; Mario P Stylianou; Carolyn J Hedin; Olanda Hathaway; Joel Moss
Journal:  Chest       Date:  2004-12       Impact factor: 9.410

4.  Decline in lung function in lymphangioleiomyomatosis: relation to menopause and progesterone treatment.

Authors:  S R Johnson; A E Tattersfield
Journal:  Am J Respir Crit Care Med       Date:  1999-08       Impact factor: 21.405

5.  Efficacy and safety of sirolimus in lymphangioleiomyomatosis.

Authors:  Francis X McCormack; Yoshikazu Inoue; Joel Moss; Lianne G Singer; Charlie Strange; Koh Nakata; Alan F Barker; Jeffrey T Chapman; Mark L Brantly; James M Stocks; Kevin K Brown; Joseph P Lynch; Hilary J Goldberg; Lisa R Young; Brent W Kinder; Gregory P Downey; Eugene J Sullivan; Thomas V Colby; Roy T McKay; Marsha M Cohen; Leslie Korbee; Angelo M Taveira-DaSilva; Hye-Seung Lee; Jeffrey P Krischer; Bruce C Trapnell
Journal:  N Engl J Med       Date:  2011-03-16       Impact factor: 91.245

6.  A 2-year randomised placebo-controlled trial of doxycycline for lymphangioleiomyomatosis.

Authors:  William Y C Chang; Jennifer L Cane; Maruti Kumaran; Sarah Lewis; Anne E Tattersfield; Simon R Johnson
Journal:  Eur Respir J       Date:  2013-12-05       Impact factor: 16.671

7.  Official American Thoracic Society/Japanese Respiratory Society Clinical Practice Guidelines: Lymphangioleiomyomatosis Diagnosis and Management.

Authors:  Francis X McCormack; Nishant Gupta; Geraldine R Finlay; Lisa R Young; Angelo M Taveira-DaSilva; Connie G Glasgow; Wendy K Steagall; Simon R Johnson; Steven A Sahn; Jay H Ryu; Charlie Strange; Kuniaki Seyama; Eugene J Sullivan; Robert M Kotloff; Gregory P Downey; Jeffrey T Chapman; MeiLan K Han; Jeanine M D'Armiento; Yoshikazu Inoue; Elizabeth P Henske; John J Bissler; Thomas V Colby; Brent W Kinder; Kathryn A Wikenheiser-Brokamp; Kevin K Brown; Jean F Cordier; Cristopher Meyer; Vincent Cottin; Jan L Brozek; Karen Smith; Kevin C Wilson; Joel Moss
Journal:  Am J Respir Crit Care Med       Date:  2016-09-15       Impact factor: 21.405

  7 in total
  3 in total

1.  Mutation spectrums of TSC1 and TSC2 in Chinese women with lymphangioleiomyomatosis (LAM).

Authors:  Jie Liu; Weiwei Zhao; Xiaohua Ou; Zhen Zhao; Changming Hu; Mingming Sun; Feifei Liu; Junhao Deng; Weili Gu; Jiaying An; Qingling Zhang; Xiaoxian Zhang; Jiaxing Xie; Shiyue Li; Rongchang Chen; Shihui Yu; Nanshan Zhong
Journal:  PLoS One       Date:  2019-12-19       Impact factor: 3.240

Review 2.  Lymphangioleiomyomatosis: a clinical review.

Authors:  Anne M O'Mahony; Evelyn Lynn; David J Murphy; Aurelie Fabre; Cormac McCarthy
Journal:  Breathe (Sheff)       Date:  2020-06

3.  Rapamycin nanoparticles improves drug bioavailability in PLAM treatment by interstitial injection.

Authors:  Yahong Shi; Chuqiao Jiao; Xi Lu; Yifeng Nie; Xiang Li; Dong Han
Journal:  Orphanet J Rare Dis       Date:  2022-09-09       Impact factor: 4.303

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.